Intellia Therapeutics, Inc (NTLA) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 6, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NTLA SEC filings page.
Intellia Therapeutics, Inc (NTLA) reported $59.5M in revenue over the twelve months to Jun 30, 2026, up 12.6% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Intellia remains a research-funded business: narrower FY2025 losses did not translate into better operating cash generation.
Earnings quality weakened: the net loss narrowed to$412.7M from$519.0M , while operating cash flow moved to-$394.7M from-$348.9M . The gap indicates that FY2025's accounting improvement was not matched by cash conversion, even as reported revenue increased.
Development spending dominates the operating model: R&D was
Cash use is primarily operational, not capital-intensive: capital expenditures were only
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Intellia Therapeutics, Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Intellia Therapeutics, Inc held $605.1M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $394.7M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Intellia Therapeutics, Inc scores 44/100 among other emerging companies.
Intellia Therapeutics, Inc had 118M shares outstanding at the end of fiscal year 2025, against 104M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Intellia Therapeutics, Inc scores 47/100 among other emerging companies.
Intellia Therapeutics, Inc spent $388.9M on research and development in fiscal year 2025, which was 76.4% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Intellia Therapeutics, Inc scores 95/100 among other emerging companies.
Intellia Therapeutics, Inc reported revenue of $67.7M in fiscal year 2025, against $57.9M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Intellia Therapeutics, Inc scores 75/100 among other emerging companies.
Intellia Therapeutics, Inc's operations used $394.7M of cash in fiscal year 2025, against $348.9M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Intellia Therapeutics, Inc scores 45/100 among other emerging companies.
Intellia Therapeutics, Inc's cash, cash equivalents and investments came to $605.1M at the end of fiscal year 2025, against $170.7M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Intellia Therapeutics, Inc scores 85/100 among other emerging companies.
Intellia Therapeutics, Inc scores 0.74, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.7B) relative to total liabilities ($170.7M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Intellia Therapeutics, Inc passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Intellia Therapeutics, Inc reported a net loss of $412.7M while operations used $394.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Intellia Therapeutics, Inc generated $7.7M in revenue in Q2 2026. This represents a decrease of 46.2% from the same quarter a year earlier. Against the prior quarter it is down 49.1%.
Intellia Therapeutics, Inc's EBITDA was -$110.7M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 2.9% from the same quarter a year earlier. Against the prior quarter it is down 12.5%.
Intellia Therapeutics, Inc reported -$106.6M in net income in Q2 2026. This represents a decrease of 5.3% from the same quarter a year earlier. Against the prior quarter it is down 10.8%.
Intellia Therapeutics, Inc earned -$0.80 per diluted share (EPS) in Q2 2026. This represents an increase of 18.4% from the same quarter a year earlier. Against the prior quarter it is up 1.2%.
Cash & Balance Sheet
Intellia Therapeutics, Inc recorded an outflow of $84.9M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 15.0% from the same quarter a year earlier. Against the prior quarter it is up 27.7%.
Intellia Therapeutics, Inc held $106.1M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Intellia Therapeutics, Inc's ROE was -14.6% in Q2 2026, measuring profit generated per dollar of shareholder equity. Against the prior quarter it is up 0.9 percentage points.
Not reported for Q2 2026.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Intellia Therapeutics, Inc invested $82.6M in research and development in Q2 2026. This represents a decrease of 14.9% from the same quarter a year earlier. Against the prior quarter it is up 2.3%.
Intellia Therapeutics, Inc invested $1.8M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 656.9% from the same quarter a year earlier. Against the prior quarter it is up 2189.9%.
Not reported for Q2 2026.
NTLA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.7M-46.2% | $15.0M-9.5% | $23.0M+78.8% | $13.8M+51.3% | $14.2M+104.8% | $16.6M-42.5% | $12.9M | $9.1M-24.0% |
| R&D Expenses | $82.6M-14.9% | $80.7M-25.5% | $88.7M-24.1% | $94.7M-23.2% | $97.0M-15.0% | $108.4M-3.1% | $116.9M | $123.4M+8.5% |
| SG&A Expenses | $37.8M+39.0% | $34.8M+20.1% | $33.1M+1.9% | $30.5M0.0% | $27.2M-14.4% | $29.0M-6.7% | $32.4M | $30.5M+3.7% |
| Operating Income | -$112.8M-2.5% | -$100.5M+16.8% | -$98.7M+27.7% | -$111.5M+23.0% | -$110.0M+20.9% | -$120.8M-6.0% | -$136.4M | -$144.8M-10.4% |
| EBITDA | -$110.7M-2.9% | -$98.3M+16.9% | -$96.3M+28.0% | -$109.1M+23.3% | -$107.5M+21.2% | -$118.3M-6.1% | -$133.9M | -$142.2M-10.4% |
| Net Income | -$106.6M-5.3% | -$96.2M+15.8% | -$95.8M+25.7% | -$101.3M+25.3% | -$101.3M+31.1% | -$114.3M-6.4% | -$128.9M | -$135.7M-11.0% |
| EPS (Basic) | -$0.80+18.4% | -$0.81+26.4% | -$0.82+34.9% | -$0.92+31.3% | -$0.98+35.5% | -$1.10+1.8% | -$1.26+13.7% | -$1.34+2.9% |
| EPS (Diluted) | -$0.80+18.4% | -$0.81+26.4% | -$0.82+34.9% | -$0.92+31.3% | -$0.98+35.5% | -$1.10+1.8% | -$1.26+13.7% | -$1.34+2.9% |
| Diluted Shares (Avg) | 133M+28.7% | 118M+14.5% | N/A | 110M+9.1% | 104M+7.0% | 104M+8.4% | N/A | 101M+13.9% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
NTLA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $857.2M-4.6% | $758.8M-23.1% | $842.1M-29.3% | $925.3M-21.1% | $898.9M-24.6% | $986.2M-21.7% | $1.2B-8.5% | $1.2B-5.6% |
| Current Assets | $527.8M+6.4% | $466.4M-15.4% | $527.7M-17.5% | $581.9M-18.1% | $495.9M-34.5% | $551.4M-37.6% | $639.9M-35.9% | $710.9M-20.4% |
| Cash & Equivalents | $106.1M-32.0% | $134.7M+6.2% | $155.5M-17.8% | $193.4M+60.5% | $156.2M+19.4% | $126.9M-26.2% | $189.2M-16.6% | $120.5M-28.3% |
| Short-Term Investments | $331.6M+9.3% | $241.3M-36.0% | $294.4M-28.6% | $317.7M-40.9% | $303.5M-45.8% | $376.9M-39.1% | $412.3M-39.8% | $537.6M-21.7% |
| Accounts Receivable | $7.3M-35.5% | $9.1M-13.1% | $9.5M+11.2% | $11.1M+24.8% | $11.4M-7.9% | $10.5M-71.2% | $8.5M-76.6% | $8.9M+36.4% |
| Long-Term Investments | $190.6M+11.6% | $141.3M-30.5% | $155.3M-40.3% | $158.8M-44.6% | $170.9M-31.3% | $203.4M+25.5% | $260.2M+160.6% | $286.6M+108.0% |
| Total Liabilities | $129.5M-92.0% | $137.8M-33.2% | $170.7M-46.5% | $176.9M-16.1% | $1.6B+632.1% | $206.2M-7.7% | $319.1M+27.2% | $210.7M+2.3% |
| Current Liabilities | $79.4M-16.9% | $76.4M-32.1% | $103.9M-6.3% | $93.7M-11.3% | $95.5M-9.1% | $112.6M+15.0% | $110.9M-3.8% | $105.7M+14.9% |
| Non-Current Liabilities | $50.1M-96.7% | $61.4M-34.4% | $66.8M-67.9% | $83.1M-20.9% | $1.5B+1216.2% | $93.7M-25.4% | $208.2M+53.5% | $105.1M-7.8% |
| Total Equity | $727.7M+201.7% | $620.9M-20.4% | $671.4M-23.0% | $748.4M-22.3% | -$715.3M-173.7% | $779.9M-24.7% | $872.0M-17.0% | $962.6M-7.2% |
| Retained Earnings | -$2.8B-16.7% | -$2.7B-17.2% | -$2.6B-19.0% | -$2.5B-21.8% | -$2.4B-25.1% | -$2.3B-29.8% | -$2.2B-31.3% | -$2.0B-34.2% |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
NTLA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$83.1M+16.6% | -$117.3M+21.2% | -$69.3M+18.7% | -$76.9M+9.4% | -$99.6M-71.2% | -$148.9M-23.4% | -$85.2M+8.4% | -$84.8M+16.3% |
| Depreciation & Amortization | $2.1M-16.0% | $2.2M-11.8% | $2.4M-7.2% | $2.4M-7.7% | $2.5M-3.8% | $2.5M-0.6% | $2.6M+4.1% | $2.6M+13.5% |
| Stock-Based Compensation | $18.1M-18.0% | $13.5M-38.3% | N/A | $19.6M-50.5% | $22.0M-46.1% | $21.8M-36.1% | N/A | $39.6M+12.1% |
| Capital Expenditures | $1.8M+656.9% | $79K-89.3% | $126K-87.2% | $29K-97.7% | $239K-76.4% | $735K-70.7% | $981K-35.5% | $1.3M-70.5% |
| Free Cash Flow | -$84.9M+15.0% | -$117.4M+21.5% | -$69.4M+19.5% | -$76.9M+10.7% | -$99.9M-68.7% | -$149.7M-21.5% | -$86.2M+8.9% | -$86.1M+18.5% |
| Investing Cash Flow | -$141.6M-232.4% | $66.3M-29.7% | $27.5M-81.8% | -$741K+90.4% | $106.9M+542.0% | $94.3M+1498.5% | $151.6M+229.9% | -$7.7M-109.7% |
| Financing Cash Flow | $196.1M+1238.5% | $33.6M | $2.0M-14.7% | $114.9M+39.7% | $14.7M-64.5% | $0-100.0% | $2.3M-97.8% | $82.2M+330.3% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
NTLA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1472.3% | -668.1% | -428.9% | -808.9% | -772.2% | -726.6% | -1059.9% | -1589.0% |
| Net Margin | -1392.3% | -639.5% | -416.2% | -735.2% | -710.8% | -687.6% | -1001.2% | -1489.5% |
| Return on Equity | -14.6% | -15.5%-0.8pp | -14.3%+0.5pp | -13.5%+0.6pp | N/A | -14.7%-4.3pp | -14.8% | -14.1%-2.3pp |
| Return on Assets | -12.4%-1.2pp | -12.7%-1.1pp | -11.4%-0.5pp | -10.9%+0.6pp | -11.3%+1.1pp | -11.6%-3.1pp | -10.8% | -11.6%-1.7pp |
| Current Ratio | 6.65+1.5x | 6.10+1.2x | 5.08-0.7x | 6.21-0.5x | 5.19-2.0x | 4.90-4.1x | 5.77-2.9x | 6.73-3.0x |
| Debt-to-Equity | 0.18 | 0.220.0x | 0.25-0.1x | 0.240.0x | N/A | 0.260.0x | 0.37+0.1x | 0.220.0x |
| Asset Turnover | 0.010.0x | 0.020.0x | 0.030.0x | 0.010.0x | 0.020.0x | 0.020.0x | 0.01 | 0.010.0x |
| FCF Margin | -1108.8% | -780.3% | -301.6% | -558.2% | -701.0% | -900.1% | -669.4% | -945.2% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Intellia Therapeutics, Inc NTLA | FY2025 | $67.7M | -$412.7M | N/A | $1.7B | 65/100 |
| Zymeworks Inc. ZYME | FY2025 | $106.0M | -$81.1M | -76.6% | $1.9B | 76/100 |
| Arcus Biosciences, Inc. RCUS | FY2025 | $247.0M | -$353.0M | N/A | $3.2B | 61/100 |
| Tourmaline Bio, Inc. TRML | FY2024 | N/A | -$73.2M | N/A | $1.2B | — |
| Dianthus Therapeutics, Inc. DNTH | FY2025 | $2.0M | -$162.3M | N/A | $4.9B | 55/100 |
| Enliven Therapeutics, Inc. ELVN | FY2025 | N/A | -$103.7M | N/A | $3.3B | — |
Where Intellia Therapeutics, Inc Ranks
Frequently Asked Questions
What is Intellia Therapeutics, Inc's annual revenue?
Intellia Therapeutics, Inc (NTLA) reported $67.7M in total revenue for fiscal year 2025. This represents a 16.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Intellia Therapeutics, Inc's revenue growing?
Intellia Therapeutics, Inc (NTLA) revenue grew by 16.9% year-over-year, from $57.9M to $67.7M in fiscal year 2025.
Is Intellia Therapeutics, Inc profitable?
No, Intellia Therapeutics, Inc (NTLA) reported a net income of -$412.7M in fiscal year 2025.
What is Intellia Therapeutics, Inc's EBITDA?
Intellia Therapeutics, Inc (NTLA) had EBITDA of -$431.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Intellia Therapeutics, Inc's return on equity (ROE)?
Intellia Therapeutics, Inc (NTLA) has a return on equity of -61.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Intellia Therapeutics, Inc's free cash flow?
Intellia Therapeutics, Inc (NTLA) recorded an outflow of $395.9M in free cash flow during fiscal year 2025. This represents a -11.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Intellia Therapeutics, Inc's operating cash flow?
Intellia Therapeutics, Inc (NTLA) recorded an outflow of $394.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Intellia Therapeutics, Inc's total assets?
Intellia Therapeutics, Inc (NTLA) had $842.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Intellia Therapeutics, Inc's capital expenditures?
Intellia Therapeutics, Inc (NTLA) invested $1.1M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Intellia Therapeutics, Inc spend on research and development?
Intellia Therapeutics, Inc (NTLA) invested $388.9M in research and development during fiscal year 2025.
What is Intellia Therapeutics, Inc's current ratio?
Intellia Therapeutics, Inc (NTLA) had a current ratio of 5.08 as of fiscal year 2025, which is generally considered healthy.
What is Intellia Therapeutics, Inc's debt-to-equity ratio?
Intellia Therapeutics, Inc (NTLA) had a debt-to-equity ratio of 0.25 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Intellia Therapeutics, Inc's return on assets (ROA)?
Intellia Therapeutics, Inc (NTLA) had a return on assets of -49.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Intellia Therapeutics, Inc's P/E ratio?
Intellia Therapeutics, Inc (NTLA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $1.7B as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Intellia Therapeutics, Inc's price-to-sales ratio?
Intellia Therapeutics, Inc (NTLA) trades at 29.1x sales, its market capitalization divided by revenue of $59.5M revenue, trailing 12 months to June 30, 2026. The market capitalization is $1.7B as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Intellia Therapeutics, Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Intellia Therapeutics, Inc (NTLA) held $605.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $394.7M over that year. Dividing the one by the other, the reported balance equals about 18 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Intellia Therapeutics, Inc's Altman Z-Score?
Intellia Therapeutics, Inc (NTLA) has an Altman Z-Score of 0.74, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Intellia Therapeutics, Inc's Piotroski F-Score?
Intellia Therapeutics, Inc (NTLA) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Intellia Therapeutics, Inc's earnings high quality?
Intellia Therapeutics, Inc (NTLA) reported a net loss of $412.7M while operations used $394.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Intellia Therapeutics, Inc?
Intellia Therapeutics, Inc (NTLA) scores 65 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.